ATH ASX Chart
Snapshot
Alterity Therapeutics Limited (ATH, formerly Prana Biotechnology Limited) is a clinical stage biotechnology company focused on neurodegenerative diseases. The company focusses to commercialise research into Parkinsonian movement disorders, Alzheimer's disease, Huntington disease and other neurodegenerative disorders.
Share Price Activity (ASX)
Last (Price) | |
Change | 0.00 (0.00) |
Bid / Ask | - |
Volume | |
Volume (4w avg) | |
Turnover | |
Open | |
Day Range | - |
VWAP | |
Prev Close | |
Last Trade |
Performance
1 Week | |
1 Month | |
2025 YTD | |
1 Year | |
vs Sector (1yr) | +142.24% |
vs ASX 200 (1yr) | +132.19% |
Announcements
Corporate Overview
Corporate Details
Head Office | Melbourne VIC 3000 |
Website | www.alteritytherapeutics.com |
Registry | Automic Group |
Auditor | PricewaterhouseCoopers |
Date Listed | 28 Mar 2000 |
Upcoming Calendar (Forecasted)
Date | Event |
---|---|
26/02/2025 | Report (Interim) |
28/08/2025 | Report (Prelim) |
25/09/2025 | Report (Annual) |
Former Company Names
- Prana Biotechnology Ltd (PBT), 11/04/2019
Sponsored Financial Content
Dividend History
DPS and Yield calculations use the Pay Date.
See Upcoming Dividends for all ASX companies.
Directors & Management
Directors
Management
Director Transactions
ATH directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
Director Interests
The current holdings of ATH directors.
Shareholder Info
Substantial Shareholders
A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.
Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.
Note: If a substantial shareholder's stake drops below 5%, the "Shareholders Selling" field shows full ownership as sold and sets "New %" to zero, even if they continue to hold shares under the limit.
Name | Last Notice | Total Shares | Shares Held (%) |
---|---|---|---|
The Bank of New York Mellon Corporation | 03/02/2025 | 2,266,681,474 | 41.28 |
Shareholders Buying
12 month transaction history compiled from ASX announcements.
Date | Name | Bought | Previous % | New % |
---|---|---|---|---|
03-02-25 | The Bank of New York Mellon Corporation | 191,999,526 | 39.55 | 41.28 |
03-02-25 | JPmorgan Chase & Co. and its affiliates | 272,198,215 | -- | 5.11 |
01-05-24 | The Bank of New York Mellon Corporation | 56,748,000 | 38.52 | 39.55 |
16-04-24 | The Bank of New York Mellon Corporation | 77,545,200 | 37.04 | 38.52 |
21-03-24 | The Bank of New York Mellon Corporation | 62,332,800 | 35.85 | 37.04 |
04-03-24 | The Bank of New York Mellon Corporation | 13,416,600 | 42.54 | 35.85 |
04-03-24 | JPmorgan Chase & Co. and its affiliates | 368,579,211 | -- | 7.04 |
27-02-24 | The Bank of New York Mellon Corporation | 56,221,200 | 41.26 | 42.54 |
Shareholders Selling
12 month transaction history compiled from ASX announcements.
Date | Name | Sold | Previous % | New % |
---|---|---|---|---|
04-02-25 | JPmorgan Chase & Co. and its affiliates | 272,198,215 | 5.11 | -- |
03-05-24 | JPmorgan Chase & Co. and its affiliates | 368,579,211 | 7.04 | -- |
Historical Data
Share Price History
Date | Close | Change | %Chg | Open | High | Low | Volume | Turnover |
---|---|---|---|---|---|---|---|---|
Historical Data
Year | Closing Price | Last Trade |
---|---|---|
2024 | $0.004 | 28 June |
2023 | $0.007 | 30 June |
2022 | $0.013 | 30 June |
2021 | $0.028 | 30 June |
2020 | $0.017 | 30 June |
2019 | $0.029 | 28 June |
2018 | $0.044 | 29 June |
2017 | $0.051 | 30 June |
2016 | $0.10 | 30 June |
2015 | $0.15 | 30 June |
2014 | $0.22 | 30 June |
Important note:
All year-end and CSV data is "as traded on the day" and ignores corporate actions (e.g. share splits)

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.